Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Resource implications of running a sacral neuromodulation service: a 10-year experience.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2014

Same author

Does sacral nerve stimulation improve global pelvic function in women?

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013

Same author

Does a learning curve exist in endorectal two-dimensional ultrasound accuracy?

Techniques in coloproctology·2012

Same author

Subarachnoid anaesthetic blockade for sacral nerve stimulator insertion.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2012

Same author

Metachronous bilateral adrenal metastases following curative treatment for colorectal carcinoma.

Annals of the Royal College of Surgeons of England·2011

Same author

The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.

The Journal of antimicrobial chemotherapy·1997

Search research articles

Related Experiment Videos

The association between prucalopride efficacy and constipation type.

A M Jadav¹, C M McMullin, J Smith

¹Colorectal Surgical Unit, Northern General Hospital, Sheffield, UK, alkajadav@hotmail.com.

Techniques in Coloproctology

|May 25, 2013

Summary

This summary is machine-generated.

Prucalopride may benefit women with chronic constipation, regardless of type. A trial is recommended to assess effectiveness for obstructed defecation syndrome, slow transit constipation, or IBS-C.

Related Experiment Videos

Area of Science:

Gastroenterology
Pharmacology

Background:

Prucalopride is a selective serotonin receptor agonist used for chronic constipation unresponsive to laxatives.
Its efficacy across different constipation subtypes, including slow transit constipation (STC), obstructed defecation syndrome (ODS), and constipation-predominant irritable bowel syndrome (IBS-C), is not well-defined.

Purpose of the Study:

To investigate the association between prucalopride efficacy and specific constipation types in women.
To determine if constipation etiology influences treatment response to prucalopride.

Main Methods:

A retrospective analysis of women receiving prucalopride between June 2010 and April 2012.
Patients were categorized into ODS, STC, mixed, or IBS-C groups based on clinical presentation and investigations.
Treatment success was defined by patient satisfaction and medication continuation after a 4-week trial.

Main Results:

Overall, 42% of 59 women showed improvement after a 4-week prucalopride trial.
Response rates varied slightly by subtype: ODS (59%), IBS-C (44%), mixed (43%), and STC (31%).
The specific type of constipation did not significantly predict treatment response (p=0.32), and 15% experienced side effects.

Conclusions:

Prucalopride demonstrates potential efficacy across various chronic constipation subtypes.
A trial of prucalopride may be beneficial for patients irrespective of their underlying constipation diagnosis.
Further research could explore long-term efficacy and optimal patient selection.